CHARACTERIZATION OF RECEPTORS FOR FMRFAMIDE RELATED NEUROPEPTIDES

FMRF酰胺相关神经肽受体的表征

• 批准号: 3860019
• 负责人: K PAYZA
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3860019
• 关键词: Mollusca; adenylate cyclase; animal tissue; biological signal transduction; cell membrane; drug interactions; hormone regulation /control mechanism; inhibitor /antagonist; nerve endings; neuropeptide receptor; neuropeptides; opiate alkaloid; oxytocin; peptide analog; perfusion; radioimmunoassay; radiotracer; receptor binding; vasopressins

This project aims to characterize the receptors for Phe-Met-Arg-Phe-NH2 (FMRFamide) and Phe-Leu-Phe-Gln-Arg-NH2 (NPFF) in mollusk and mammalian CNS, respectively. Radioactive analogs of NPFF and FMRFamide were prepared for developing receptor binding assays in membrane preparations. A multichannel perfusion apparatus was constructed to study the effects of NPFF on secretion of oxytocin and vasopressin from isolated nerve endings of the rat neural lobe. An antibody to a cAMP analog was characterized in a cAMP RIA to measure neuropeptide-stimulated adenylate cyclase activity in membrane preparations. The proposed course of this project includes (1) study of ligand binding to NPFF receptors, (2) development of specific NPFF antagonists, (3) investigation of the coupling of NPFF receptors to cellular signal transduction systems, (4) study of the physiological and behavioral effects of NPFF and its antagonists, including interactions with opiods, and (5) isolation of NPFF and FMRFamide receptors from bovine and squid CNS respectively.

该项目旨在表征 Phe-Met-Arg-Phe-NH2 受体 软体动物和哺乳动物中的 (FMRFamide) 和 Phe-Leu-Phe-Gln-Arg-NH2 (NPFF) 分别是中枢神经系统。 制备了 NPFF 和 FMRFamide 的放射性类似物 用于开发膜制剂中的受体结合测定。 一个 构建多通道灌注装置来研究 NPFF 对离体神经末梢分泌催产素和加压素的影响 大鼠神经叶。 cAMP 类似物的抗体的特征在于 cAMP RIA 测量神经肽刺激的腺苷酸环化酶活性 膜制剂。 该项目拟议的课程包括（1）配体结合的研究 NPFF 受体，(2) 开发特定的 NPFF 拮抗剂，(3) NPFF受体与细胞信号耦合的研究 转导系统，（4）生理和行为效应研究 NPFF 及其拮抗剂，包括与阿片类药物的相互作用，以及 (5) 从牛和鱿鱼中枢神经系统中分离 NPFF 和 FMRFamide 受体 分别。